Aurinia Pharmaceuticals Inc (AUPH)

NASDAQ
16.26
-1.77(-9.82%)
After Hours
16.20
-0.06(-0.37%)
- Real-time Data
  • Volume:
    5,510,408
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    15.93 - 17.89

AUPH Overview

Prev. Close
18.03
Day's Range
15.93-17.89
Revenue
72.32M
Open
17.86
52 wk Range
9.74-33.97
EPS
-1.21
Volume
5,510,408
Market Cap
2.11B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
4,574,634
P/E Ratio
-
Beta
0.82
1-Year Change
9.42%
Shares Outstanding
129,670,345
Next Earnings Date
Mar 18, 2022
What is your sentiment on Aurinia Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Aurinia Pharmaceuticals Inc Company Profile

Employees
294

Aurinia Pharmaceuticals Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases. The Company has developed LUPKYNISTM, for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory advancement to support the voclosporin development program. LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil and steroids. LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. It also focuses on treatment of autoimmune, fibrotic, and kidney-related diseases. Its product pipeline includes AUR200, AUR300.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellStrong SellStrong SellSell
Technical IndicatorsSellStrong SellStrong SellStrong SellBuy
SummarySellStrong SellStrong SellStrong SellNeutral
  • Offering??
    0
    • Back in for some at 2.7
      0
      • I sold out yesterday right before close. Will get back in early January. Technicals look too choppy.
        0
        • Let's fill the gap before year end.
          0
          • Very interesting Jan call volume.
            0
            • ya, this board and $sabs board dead on this site :)
              0
              • GSK Chatter. What does that mean?
                0
                • Ok, asked a friend since this board seems dead. Rumors nothing more than that. Been down this rodeo before. Holding regardless of buyout or GIA. Solid opportunity to double from here IMO.
                  0
              • Nice volume!!
                0
                • Absolutely no volume. Power Hour should be interesting.
                  0
                  • added at 19
                    0
                    • gona keep a tight stop loss, under 50 dma
                      0
                    • got out at 19 after that swing to the 17s.... mbe get some tomorrow in the 17s..
                      0
                  • Nice drop. I will add more here.
                    0
                    • nice volume early in the morning.
                      0
                      • I am buying the dip. If it goes to 21.75 I will be 100% in AUPH.
                        0
                        • "Read between the lines"
                          0
                          • BMY scraps their LN drug today (BMS-986165). Looks suspicious to me.
                            0
                            • Drop the Mic!
                              0
                              • Trading like an offering coming.
                                0
                                • How long you had known this? Looks like an insider trade :)
                                  0
                                • @ Theodore Striker how did you know that please ?
                                  0
                                • I didnt know this, however, based on the trading it looked like someone would come in and buy them. Why would they delist from TSX, insiders selling shares probably required by purchasing company, buy two small biotechs (BP probably told them to buy them which would be much cheaper to get from AUPH than BP doing it). I could go on and on but it sure looked like something was brewing. If they get bought out at $30 pps I will be very shocked.
                                  0
                              • Looking for 21.71
                                0
                                • Looks like she might get there.
                                  0
                                • got it!
                                  0
                                • regret it. lol
                                  0
                              • I stopped out at 23.
                                0
                                • You did good. I chickened out at 20.
                                  0
                              • Shorts all underwater now.
                                0
                                • MM's getting squeezed on options? Hmmmm...
                                  0
                                  • Nice! This could be a case study as to why so many hedge funds go under. Shorting something that will at a minimum double your money in due time.
                                    1
                                    • Trying to get those options out of money. lol!
                                      0
                                      • shorts running out of powder?
                                        0
                                        • Shorts have strong conviction. Could gamma squeeze this week? I would like to see it. OOO AAAH
                                          0
                                          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.